Abstract

OPTIMIZING HEART FAILURE MANAGEMENT WITH SACUBITRIL/VALSARTAN: A COMPREHENSIVE REVIEW

Dipti Shivajirao Burle*, Priti Diliprao Makne, Siddheshwar Sangram Patil, Sudarshan Ranjit Jadhav

.

Abstract

Heart failure treatment has improved dramatically over the past 30 years, saving lives and reducing hospital stays. Despite this progress, heart failure remains a major health concern, causing frequent hospitalizations, long-term care, and significant economic burden. A medication called sacubitril has become a crucial treatment for patients with heart failure. Recent breakthroughs in sacubitril therapy have transformed the management of heart failure, offering better outcomes, fewer side effects, and improved quality of life. However, the affordability of sacubitril remains a concern in developing countries. Heart failure is a major health concern worldwide, causing many deaths and illnesses. It also has a significant economic impact due to its high prevalence, frequent hospital visits, long-term care, missed workdays, and increased risk of death. For nearly 20 years, standard treatments for heart failure have included ACE inhibitors, ARBs, and beta-blockers. Although these treatments are effective and affordable, they haven't been able to reduce hospital readmissions or improve quality of life for heart failure patients.

Keywords: Sacubitril, Heart failure, ACE inhibitor, Beta blockers.